PT  - JOURNAL ARTICLE
AU  - Murray, Daniel D.
AU  - Babiker, Abdel G.
AU  - Baker, Jason V.
AU  - Barkauskas, Christina E.
AU  - Brown, Samuel M.
AU  - Chang, Christina
AU  - Davey, Victoria J.
AU  - Gelijns, Annetine C.
AU  - Ginde, Adit A.
AU  - Grund, Birgit
AU  - Higgs, Elizabeth
AU  - Hudson, Fleur
AU  - Kan, Virginia L.
AU  - Lane, H. Clifford
AU  - Murray, Thomas A.
AU  - Paredes, Roger
AU  - Parmar, Mahesh K.B.
AU  - Pett, Sarah
AU  - Phillips, Andrew N.
AU  - Polizzotto, Mark N.
AU  - Reilly, Cavan
AU  - Sandkovsky, Uriel
AU  - Sharma, Shweta
AU  - Teitelbaum, Mark
AU  - Thompson, B. Taylor
AU  - Young, Barnaby E.
AU  - Neaton, James D.
AU  - Lundgren, Jens D.
AU - on behalf of the TICO study group
TI  - Design and implementation of the multi-arm, multi-stage Therapeutics for Inpatients with COVID-19 (TICO) platform master protocol: An Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative
AID  - 10.1101/2020.11.08.20227876
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.08.20227876
4099  - http://medrxiv.org/content/early/2020/11/13/2020.11.08.20227876.short
4100  - http://medrxiv.org/content/early/2020/11/13/2020.11.08.20227876.full
AB  - Background The SARS-CoV-2 pandemic is a public health emergency. Safe and effective therapies are urgently needed.Methods Therapeutics for Inpatients with COVID-19 (TICO), is a global multi-arm, multi-stage (MAMS) platform master protocol, which facilitates the rapid evaluation of the safety and efficacy of candidate anti-viral therapeutic agents for adults hospitalized with COVID-19. The protocol design allows multiple therapeutic agents to be evaluated in an efficient and scientifically rigorous manner, with efficiencies delivered by the MAMS design, and began by studying neutralizing monoclonal antibodies. TICO employs an agile and robust approach to futility and safety evaluation at 300 patients enrolled (Stage 1), with subsequent expansion to full sample size and an expanded target population (Stage 2) if the agent shows an acceptable safety profile and evidence of efficacy. Two ordinal outcomes applied early (Day 5) determine the efficacy signals of the investigational agents(s) and progression to Stage 2. These ordinal outcomes assess both respiratory and other organ failure events, recognizing the broad range of COVID-19 morbidity. In Stage 2, overall efficacy is assessed using the primary outcome of ‘time to sustained recovery’ assessed over 90 days. This approach to early futility assessment using an early intermediate outcome and a primary endpoint out to 90 days allows the study team to make rapid decisions on safety and potential efficacy of novel agents while ultimately focusing on patient-centered, longer-term outcomes. The implementation of TICO across a global network allows for continued enrollment despite variations in geographic epidemiology.Study Status The TICO master protocol moved from conception to first patient enrolled in approximately 9 weeks, a testament to the expedited regulatory and ethics review, coupled with flexible and responsive study operations. The first agent to be tested using this protocol, LY-CoV-555, enrolled N=326 participants before undergoing Stage 1 futility and safety assessment. Two additional agents will enter the study in November 2020, with other agents planned.Conclusion The TICO MAMS platform trial has been implemented efficiently across a global network of sites and several trial networks. It will generate results rapidly for multiple novel neutralizing monoclonal antibodies and other therapeutics agents.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04501978Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04501978?term=NCT04501978&draw=2&rank=1 Funding StatementTICO is funded primarily through Operation Warp Speed (sub-contracted through Leidos Biomedical Research Inc.). Additional funding was provided by the NIH (including NHLBI, NIAID), U.S. Department of Veterans Affairs, as well as the governments of governments of Denmark (National Research Foundation; grant no 126), Australia (National Health and Medical Research Council), and U.K. (Medical Research Council, MRC_UU_12023/23).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Central IRB approval in the U.S. was recieved from Advarra (IORG 0000635 and IRB reg number 00000971). All countries and local sites that will participate in this study are also required to gain approval from relevant local bodies.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is no data relevant to this manuscript